Tyme Technologies (Tyme Technologies) Total Current Liabilities : $5.62 Mil (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Tyme Technologies's total current liabilities for the quarter that ended in Jun. 2022 was $5.62

Tyme Technologies Total Current Liabilities Historical Data

The historical data trend for Tyme Technologies's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies Total Current Liabilities Chart

Tyme Technologies Annual Data

Trend Nov12 Nov13 Nov14 Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22

Total Current Liabilities

Get a 7-Day Free Trial 4.55 6.21 5.58 5.64 7.39

Tyme Technologies Quarterly Data

Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22

Total Current Liabilities Get a 7-Day Free Trial 4.63 4.77 5.45 7.39 5.62

Tyme Technologies Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Tyme Technologies's Total Current Liabilities for the fiscal year that ended in Mar. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 3.545 + 0.037

+ Other Current Liabilities + Current Deferred Liabilities

= 3.804 + 0

= 7.39

Tyme Technologies's Total Current Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.91 + 0.026

+ Other Current Liabilities + Current Deferred Liabilities

= 4.685 + 0

= 5.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Tyme Technologies Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Tyme Technologies's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyme Technologies (Tyme Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Total Current Liabilities

Comparable Companies

MBRX ATXS IMMX TRVN OCUP ONCT COCP RGLS ITRM PCSA OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122

Traded in Other Exchanges

N/A

Address

1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921

Website

https://www.tymeinc.com

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Executives

Michael Demurjian director, 10 percent owner, officer: Chief Operating Officer 157 BROAD STREET SUITE 304 RED BANK NJ 07701

Steve Hoffman director, 10 percent owner, officer: CEO and Chief Science Officer 44 WALL STREET 12TH FLOOR NEW YORK NY 10005

Christine D. Baker director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118

James Biehl director 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005

Frank L. Porfido officer: Chief Financial Officer C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921

Barbara Galaini officer: Corporate Controller 17 STATE STREET 7TH FLOOR NEW YORK NY 10004

David Carberry director 44 WALL STREET 12TH FLOOR NEW YORK NY 10005

Van Tornout Jan M officer: Acting Chief Medical Officer 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921

Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139

Douglas A Michels director 220 EAST FIRST STREET, BETHLEHEM PA 18015

John M. Rothman officer: EVP, Product Development 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921

Ben R Taylor officer: President and CFO 44 WALL STREET 12TH FLOOR NEW YORK NY 10005

Michele Ilene Korfin officer: Chief Operating Officer 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004

Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879

Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

Tyme Technologies (Tyme Technologies) Headlines

From GuruFocus

TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results
By GuruFocusNews GuruFocusNews • 06-04-2022

SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.
By PRNewswire PRNewswire • 07-06-2022

TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
By Business Wire Business Wire • 12-09-2021

Thinking about buying stock in Exela Technologies, Tyme Technologies, Carnival Corp, Precigen, or Akerna?
By PRNewswire PRNewswire • 07-05-2022

TYME Technologies, Inc. Announces Changes to its Board of Directors
By Business Wire Business Wire • 03-25-2022

TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
By Business Wire Business Wire • 12-14-2021

TYME TECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME
By PRNewswire PRNewswire • 07-28-2022

TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference
By Business Wire Business Wire • 01-03-2022

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
By Business Wire Business Wire • 09-27-2021

Thinking about buying stock in Exela Technologies, Tyme Technologies, Carnival Corp, Precigen, or Akerna?
By PRNewswire PRNewswire • 07-15-2022

Tyme Technologies Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Current Liabilities	Get a 7-Day Free Trial															4.63	4.77	5.45	7.39	5.62

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	3.545	+	0.037
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	3.804	+	0
	=	7.39

Michael Demurjian	director, 10 percent owner, officer: Chief Operating Officer	157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman	director, 10 percent owner, officer: CEO and Chief Science Officer	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl	director	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido	officer: Chief Financial Officer	C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini	officer: Corporate Controller	17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry	director	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M	officer: Acting Chief Medical Officer	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman	officer: EVP, Product Development	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor	officer: President and CFO	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin	officer: Chief Operating Officer	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105